Phase 1 Glioblastoma Clinical Trials
104 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 104 trials
Recruiting
Phase 1Phase 2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
GlioblastomaGliomaMedulloblastoma+1 more
National Cancer Institute (NCI)146 enrolled1 locationNCT06161519
Recruiting
Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Pancreatic CancerLung CancerColon Cancer+3 more
RasCal Therapeutics, Inc.134 enrolled3 locationsNCT04678648
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled41 locationsNCT06860594
Recruiting
Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Phase 1
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
GlioblastomaGliosarcoma
Memorial Sloan Kettering Cancer Center60 enrolled9 locationsNCT06934889
Recruiting
Phase 1Phase 2
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Phase 1
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07480941
Recruiting
Phase 1
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled17 locationsNCT06894979
Recruiting
Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Glioblastoma
Dana-Farber Cancer Institute56 enrolled2 locationsNCT02287428
Recruiting
Phase 1Phase 2
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
MGMT-Unmethylated GlioblastomaHigh Grade GliomaMGMT-Methylated Glioblastoma
University of California, San Francisco70 enrolled5 locationsNCT06504381
Recruiting
Phase 1
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting
Phase 1
CUE-102 in Recurrent Glioblastoma
GlioblastomaGlioma, MalignantRecurrent Glioblastoma
David Reardon, MD18 enrolled2 locationsNCT06917885
Recruiting
Phase 1Phase 2
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Glioblastoma Multiforme
Neonc Technologies, Inc.49 enrolled12 locationsNCT02704858
Recruiting
Phase 1Phase 2
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1Phase 2
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled17 locationsNCT05765812
Recruiting
Phase 1
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 1Phase 2
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Glioblastoma
M.D. Anderson Cancer Center45 enrolled2 locationsNCT06672575
Recruiting
Phase 1Phase 2
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
Newly Diagnosed Glioblastoma
Assistance Publique - Hôpitaux de Paris35 enrolled5 locationsNCT06622434